During the second-annual Uromigos Live & Unplugged event, Brian Rini, MD, FASCO; Michael Morris, MD; Rana McKay, MD; Tanya Dorff, MD; and Neeraj Agarwal, MD, discuss and deliberate on new data related to radioligand therapies in prostate cancer, including a recap of the VISION trial data and an in-depth look at the PSMAfore trial data, as well as how current practice patterns should be altered as a result of new understandings. ...
The Uromigos Live & Unplugged: Prostate Cancer
Advertisement
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Drs. Dorff and Agarwal share how crucial it is for mPC patients around the world to undergo germline or somatic testing.
Drs. Hope and Agarwal provide an overview of the SOC for 1L mCRPC prior to TALAPRO-2 and how the SOC has since changed.
Drs. Dorff and Agarwal summarize the toxicities associated with talazoparib for patients with metastatic CRPC.
Drs. Dorff and Agarwal discuss the goals of the TALAPRO-2 study and further understandings that subset analyses provided.
Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field.
Michael Morris, MD, discusses radioligand therapy for prostate cancer, including common practices and new data.
Dr. Park shares why it is too soon to tell if there is survival benefit to gain from Lu-177 PSMA-617 prior to chemotherapy.
Dr. Hamid describes how PSMAfore impacts treatment sequencing in mCRPC and how future trials can strengthen control arms.
Dr. Alan Tan compares the PSMAfore and VISION studies and comments on the controversy regarding OS benefit in the former.
Brian is joined by Drs. Agarwal, Dorff, McKay, and Morris to review the state of radioligand therapy.
Dr. Morris talks about potential topics to be discussed at the event, such as the PSMAfore trial and data from ESMO.
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Advertisement
